Arcadia Biosciences held its Annual Meeting on September 10, 2026, where stockholders approved the 2026 Omnibus Equity Incentive Plan and authorized a reverse stock split with a ratio between 1-for-2 and 1-for-10 to be determined by the Board before June 30, 2027. The company also ratified the appointment of Ramirez Jimenez International CPAs as its independent auditor and approved the issuance of common stock upon exercise of Series A-1 Preferred Investment Options from a private placement closed on June 12, 2026. Gregory D. Waller was elected as a Class II director, and executive compensation received an advisory approval. Arcadia Biosciences operates in the agricultural biotechnology industry, developing crop traits to improve yield and sustainability.
